Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04332523 · ClinicalTrials.gov registry record · Phase 1
A Study of JNJ-53718678 in Participants With Hepatic Impairment
A Phase 1 study, sponsored by Janssen Research & Development.
- Terminated
- Registry status
- Phase 1
- Development phase
- 25
- Enrollment target
NCT04332523 is a Phase 1 study that was terminated before completion, run by Janssen Research & Development. The registered enrollment target is 25 participants.
The verdict
NCT04332523, a Phase 1 study, was terminated before completion, sponsored by Janssen Research & Development.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 25 participants
- Enrollment target
Study Summary
The main purpose of the study is to evaluate the pharmacokinetc (PK) of a single oral dose of JNJ-53718678 in participants with varying degrees of impaired hepatic function (mild, moderate, and severe) when compared with participants with normal hepatic function.
Interventions
- DRUG JNJ-53718678
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2020-08-17 |
| Est. Completion | 2022-03-16 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04332523
The ClinicalTrials.gov registry entry for NCT04332523 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Janssen Research & Development, which has 593 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which JNJ-53718678 is the first listed.
NCT04332523 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04332523 about?
NCT04332523 is a clinical study titled "A Study of JNJ-53718678 in Participants With Hepatic Impairment". The main purpose of the study is to evaluate the pharmacokinetc (PK) of a single oral dose of JNJ-53718678 in participants with varying degrees of impaired hepatic function (mild, moderate, and severe) when compared with participants with normal hepatic function.
What is the current status of trial NCT04332523?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 25 participants. The study started on 2020-08-17. Estimated completion is 2022-03-16.
What interventions are being tested in trial NCT04332523?
The interventions under investigation include: JNJ-53718678 (DRUG).
Who is sponsoring clinical trial NCT04332523?
This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.